Company Overview
About Eli Lilly
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Business Model & Competitive Advantage
Lilly's GLP-1 drug platform addresses the global obesity and type 2 diabetes epidemic through a dual mechanism tirzepatide formulation that simultaneously activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors — producing 15-22.5% average body weight reduction in clinical trials that surpasses the single-receptor GLP-1 agonists (like Ozempic/Wegovy from Novo Nordisk), which achieve 12-15% weight loss. This incremental efficacy advantage (the 22.5% maximum-dose result from the SURMOUNT-1 trial) creates the prescribing preference among endocrinologists and obesity medicine specialists that drives Mounjaro/Zepbound adoption despite Novo Nordisk's Ozempic first-mover advantage in the GLP-1 market. The concurrent approval of Zepbound for obstructive sleep apnea (2024, the first weight-loss drug approved for OSA) expands the treatable patient population beyond diabetes/obesity into a new therapeutic indication.
Competitive Landscape 2025–2026
In 2025, Lilly competes in the GLP-1 weight loss, type 2 diabetes treatment, and Alzheimer's disease pharmaceutical market with Novo Nordisk (NASDAQ: NVO, Ozempic/Wegovy, ~$34B 2024 revenue), Roche (SIX: ROG, Alzheimer's and oncology), and AstraZeneca (NASDAQ: AZN, diabetes and oncology) for GLP-1 prescription volume, cardiometabolic disease management market share, and Alzheimer's therapeutic adoption. The $1 trillion market capitalization reflects investor conviction in Lilly's 10-year growth runway: obesity treatment addressable market estimates range from $50-100 billion annually by 2030 (with only 3-5% of eligible patients currently prescribed GLP-1 drugs), oral orforglipron (if approved) would remove the injection barrier for the majority of obesity patients who decline injectable treatment. The 2025 strategy focuses on expanding Mounjaro/Zepbound manufacturing capacity to reduce supply constraints, launching orforglipron in Phase 3 for obesity and diabetes, and commercializing Kisunla for Alzheimer's through neurologist prescribing education.
The Eli Lilly Story
Founders
Company Timeline
Major milestones in Eli Lilly's journey
Leadership Team
Meet the leaders behind Eli Lilly
David A. Ricks
David A. Ricks has served as CEO since January 2017 and was elected Chair of the board in June 2017. He joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into international leadership positions. Under his leadership, Lilly has delivered record R&D output and business results, positioning the company for strong growth. In 2024, Ricks earned $114 million in compensation as the company achieved historic milestones.
Dr. Ruth Gimeno
Dr. Gimeno leads Lilly's global research and development efforts, overseeing the company's pipeline of innovative medicines and ensuring scientific excellence across all therapeutic areas.
Ilya Yuffa
Ilya Yuffa leads multiple critical business units including immunology therapeutics, U.S. operations, and customer relations, driving commercial success and patient access.
Diogo Rau
Diogo Rau oversees Lilly's information technology infrastructure and digital transformation initiatives, enabling data-driven innovation and operational excellence.
Mike Harrington
Mike Harrington leads Lilly's diabetes business unit, which includes blockbuster products like Mounjaro, Zepbound, Trulicity, and Humalog, representing the company's largest revenue segment in 2024.
Maria Louzao
Maria Louzao oversees Lilly's global manufacturing operations, including the planned $5 billion facility in Virginia for bioconjugates and monoclonal antibodies.
Anne White
Anne White leads Lilly's neuroscience division, including development and commercialization of Alzheimer's disease treatments like Kisunla (donanemab).
Jacob Van Naarden
Jacob Van Naarden leads Loxo@Lilly, the company's oncology research unit focused on developing precision medicines for cancer treatment.
Open Positions
Reddit Discussions
Key Differentiators
Market Leader
Eli Lilly is recognized as a market leader in the Healthcare sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $45000M in revenue, Eli Lilly operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Zeffy
Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs
Oda Studio
Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Kindful
Kindful is a donor management and fundraising platform designed for nonprofit organizations to manage relationships, track donations, and execute fundraising campaigns. The company serves small to mid
Hermes Robotics
Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Compare Eli Lilly with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Eli Lilly? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Eli Lilly Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Eli Lilly vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →